NEW YORK (GenomeWeb) – BG Medicine reported after the close of the market on Friday that its second quarter revenues plummeted 37 percent year over year as it narrowed its net loss.

For the three months ended June 30, the Waltham, Massachusetts-based firm reported total revenues of $505,000 compared to $799,000 in the year-ago period.

The company's Q2 net loss was $2.0 million, or $.23 per share, compared to a net loss of $2.2 million, or $.26 per share, in the year-ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.